APP

Across TCGA pan-cancer cohorts, APP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APP data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher APP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APP expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where APP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.305	0.544	.001	51	view →
CCRCC	DFS	Tertile	All	0.546	0.852	.001	28	view →
LSCC	DFS	Tertile	All	0.467	1.000	.013	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	5	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APP–PDAC (DFS)

Open the PDAC breakdown →